Home Tags Trodelvy

Tag: Trodelvy

Antibody-drug Conjugate Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer

Danielle Garcia -

ASCO 2025: Combination Sacituzumab Govitecan + Pembrolizumab Reduces Risk of Disease...

Danielle Garcia -

US FDA Approves Gilead’s Sacituzumab Govitecan In Pre-treated HR+/HER2- Metastatic Breast...

Editorial Team -

Sacituzumab Govitecan Shows Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2-...

Danielle Garcia -
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2022: Sacituzumab Govitecan Show PFS Benefits in Patients Diagnosed with...

Danielle Garcia -

Potential Withdrawal of Accelerated Approved Therapeutic Agents may harm Cancer Patients

Peter Hofland -

ESMO 2020: Sacituzumab Govitecan Shows 27% ORR in Heavily-pretreated Metastatic Urothelial...

Editorial Team -
Triple negative breast cancer cells showing abnormal expression basal-like markers not found on normal breast epithelial cells. Cells are stained with cytokeratins 14 (green) and 19 (red). Photo courtesy: Bill Schmitt.

ESMO 2020: Sacituzumab Govitecan Significantly Extends Overall Survival in Patients with...

Editorial Team -

ESMO 2020: Encouraging Early-Stage Clinical Results with Sacituzumab Govitecan in Brain...

Editorial Team -

LATEST NEWS